Pfizer is busy downsizing from health-care conglomerate to a focused pharmaceutical company. It sold off its nutrition business to Nestle for $12 billion and spun out 20% of its animal health division into a new company, Zoetis, for more than $2 billion.

The big pharma announced today that it plans to get rid of its remaining 80% position in the animal health company on June 19 and is even willing to swap out its Zoetis shares on sale!

In this video, health-care analyst David Williamson discusses what these events mean for investors in Pfizer and Zoetis and gives his take on the company's breakup.

David Williamson owns shares of Pfizer. Follow David on Twitter @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.